Khairoun I, Boltong M G, Driessens F C, Planell J A
Department of Materials Science and Metallurgy, Universitat Politècnica de Catalunya, Barcelona, Spain.
Biomaterials. 1997 Dec;18(23):1535-9. doi: 10.1016/s0142-9612(97)80005-1.
Clinical requirements for calcium phosphate bone cements were formulated in terms of the initial setting time, the final setting time, the cohesion time and the ultimate compressive strength. Three cement formulations were tested. The previously developed Biocement H was made of a powder containing alpha-tertiary calcium phosphate and precipitated hydroxyapatite. Biocement B2 powder was made by adding some CaCO3 to Biocement H, whereas Biocement B1 was made by adding some CaCO3 but with simultaneous adjustment of the amount of precipitated hydroxyapatite.The liquid/ powder ratio of the cement paste and the accelerator concentrations (percentage Na2HPO4) in cement liquid were varied. For Biocement H there was no combination of L/P ratio and percentage Na2HPO4 for which all clinical requirements were satisfied. However, there was an area of full compliance for Biocements B1 and B2, of which that for B1 was the largest. Therefore, Biocement B1 may be applied in clinical situations as those in orthopaedics, plastic and reconstructive surgery and oral and maxillofacial surgery, even when early contact with blood is inevitable.
磷酸钙骨水泥的临床要求是根据初凝时间、终凝时间、凝聚时间和极限抗压强度来制定的。测试了三种水泥配方。先前开发的生物水泥H由含有α-磷酸三钙和沉淀羟基磷灰石的粉末制成。生物水泥B2粉末是通过向生物水泥H中添加一些碳酸钙制成的，而生物水泥B1是通过添加一些碳酸钙但同时调整沉淀羟基磷灰石的量制成的。水泥浆的液/粉比和水泥液体中的促进剂浓度（Na2HPO4百分比）有所变化。对于生物水泥H，不存在能满足所有临床要求的液/粉比和Na2HPO4百分比的组合。然而，生物水泥B1和B2存在完全符合要求的区域，其中B1的符合区域最大。因此，即使不可避免地会早期接触血液，生物水泥B1也可应用于骨科、整形和重建手术以及口腔颌面外科等临床情况。
